Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review
- 17 October 2018
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 20 (6) , 555-566
Abstract
Cystic fibrosis is the most common inherited condition in the Caucasian population and is associated with significantly reduced life expectancy. Recent advances in treatment have focussed on addressing the underlying cause of the condition, the defective production, expression and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Several drugs with different modes of action have produced promising results in clinical trials, and some have been incorporated into routine clinical care for specific patients in many countries worldwide. Further trials continue to explore the safety and efficacy of these drugs in the youngest age groups and to search for more effective therapies to treat the most common disease-causing gene mutations in an ever-expanding drug pipeline. As evidence mounts for the early onset of disease in young patients, the prospect of introducing disease-modifying therapy in early life becomes more pertinent, although the cost implications of these expensive drugs are significant. In this review, we summarise these new therapy advances and review those currently being explored in clinical trials.Keywords
This publication has 60 references indexed in Scilit:
- Magnetic Resonance Imaging of Cystic Fibrosis Lung DiseaseJournal of Thoracic Imaging, 2013
- Abnormal endocrine pancreas function at birth in cystic fibrosis ferretsJournal of Clinical Investigation, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences, 2011
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationThorax, 2011
- The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung diseasePediatric Pulmonology, 2010
- Lung clearance index in CF: a sensitive marker of lung disease severityThorax, 2007
- Spirometry in Early Childhood in Cystic Fibrosis PatientsChest, 2007
- Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop MutationsNew England Journal of Medicine, 2003
- Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and ChildrenNew England Journal of Medicine, 2003